Sage Therapeutics presents promising results from LUMINARY Study Data presented during the Emerging Science Session at the American Academy of Neurology’s Annual Meeting, April 2022 The LUMINARY Study is a Phase 2, open-label study evaluating the safety, tolerability and efficacy of SAGE-718 once daily in individuals with mild cognitive impairment and mild dementia due to…
Liraglutide Improves Non-Motor Function and Activities of Daily Living in Patients with Parkinson’s disease
Abstract of poster presented at the AAN 2022, by Michele Tagliati, MD, FAAN Treatment with liraglutide improves critical features of PD, including non-motor symptoms and activities of daily living. These results validate similar outcomes reported with other GLP-1 agonists in PD and offer new strategies to treat the constellation of PD symptoms. BackgroundInsulin resistance (IR)…
Cenobamate (ONTOZRY®) now available in The Netherlands
Angelini Pharma, an international pharmaceutical company part of the privately held Italian Angelini Group announced on 4 April 2022 that ONTOZRY® (cenobamate) is now available in the Netherlands for the adjunctive treatment of focal-onset seizures with or without secondary generalisation in adults patients who have not been adequately controlled despite an history of treatment with…
UPLIZNA® (inebilizumab-cdon) Effective for People with Newly-Presenting Neuromyelitis Optica Spectrum Disorder (NMOSD)
Horizon Therapeutics plc announced on 31 March, 2022 the presentation of a post-hoc analysis from the N-MOmentum Phase 3 pivotal trial of UPLIZNA, showing that the medicine was safe and effective in NMOSD patients who were treated with UPLIZNA after having only one attack. These data were presented during a poster session at the American Academy…
Kesimpta®▼(ofatumumab): No increased risk of severe COVID-19 infections for adults with RRMS
• Novartis announces that the peer-reviewed journal Neurology and Therapy1 has published new data on COVID-19 infections in people living with relapsing remitting multiple sclerosis (RRMS) treated with Kesimpta® (ofatumumab) • A very small proportion (1.5%) of those fully vaccinated and treated with ofatumumab developed COVID-19. Despite being fully or partially vaccinated all patients with…
Benefits of Ocrelizumab in SPMS and PPMS
New Data for Genentech’s Ocrevus (ocrelizumab) show benefit in disability progression and cognitive decline in both Secondary Progressive and Primary Progressive Multiple Sclerosis – 75% of patients with secondary progressive multiple sclerosis (SPMS) and primary progressive MS (PPMS) achieved no evidence of progression (NEP) in a one-year interim analysis of CONSONANCE study – 70% of…
Data support body of evidence for ocrelizumab
Genentech, a member of the Roche Group, announced new Ocrevus® (ocrelizumab) data on 4th April 2022 that show its benefit on disease progression and cognitive outcomes in primary progressive multiple sclerosis (PPMS) and secondary progressive MS (SPMS). Separate analyses on treatment disparities among newly diagnosed patients with MS by race and ethnicity were presented at the…
The first cell treatment for chronic motor deficit from TBI?
SB623 Demonstrated Sustained Improvement in Motor Impairment up to 48 Weeks and Associated with Improvement in Function and Activities of Daily Living in Patients with Chronic Traumatic Brain Injury Positive results from the one-year analysis of the Phase 2 STEMTRA trial were presented for the first time at the 2022 American Academy of Neurology (#AAN2022)…
Ublituximab trials in Multiple Sclerosis
TG Therapeutics, Inc. announced data from the ULTIMATE I & II Phase 3 trials evaluating ublituximab in patients with relapsing forms of multiple sclerosis (RMS) at the American Academy of Neurology (#AAN2022) annual meeting, 2-7 April 2022 in Washington, USA. Highlights of the presentations are outlined below. We are pleased to present additional analyses from…
